EBS - צמיחת הכנסות ב-12 חודשים נגררים Emergent BioSolutions

Emergent BioSolutions is reducing its reliance on government contracts by expanding into the retail pharmaceutical market, while antidote sales help mitigate liquidity shortages. Year-over-year sales dynamics over the last four quarters confirm these trends, where -17.60 characterizes this valuation parameter. The reliability of emergency biological delivery systems remains a critical factor for ensuring national security.

This indicator measures rolling year revenue dynamics, allowing investors to assess the actual pace of business expansion without seasonal distortions. By analyzing the current sales growth rate over a rolling 12-month period year-over-year on the GURU.Markets platform, one can differentiate systemic demand from one-off contracts, which is critical for the monopolist Emergent BioSolutions (EBS), which possesses exclusive pricing power over strategic antidotes.